PAPAVERINE HYDROCHLORIDE

1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; Chlorhydrate de papaverine;  6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline hydrochloride;

PAPAVERINE HYDROCHLORIDE

 

PRODUCT IDENTIFICATION

CAS RN

61-25-6, 58-74-2(parent)

EINECS RN

200-502-1

FORMULA

C20H21NO4·HCl

MOLE WEIGHT

375.85

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

white crystalline powder

MELTING POINT

226 C

BOILING POINT

 

DENSITY

 

SOLUBILITY IN WATER

50 mg/ml

pH

 

VAPOR DENSITY

 

REFRACTIVE INDEX

 

FLASH POINT

 

 

STABILITY AND REACTIVITY
STABILITY Stable under normal conditions. May discolor on exposure to light.

INCOMPATIBLE MATERIALS

Strong oxidizing agents

DECOMPOSITION PRODUCTS

Carbon monoxide, Carbon dioxide, Nitrogen oxides, Hydrogen chloride

POLYMERIZATION Has not been reported

NFPA RATINGS

Health:2 , Flammability:0 , Reactivity:1

 

SAFETY

HAZARD NOTES

Toxic (USA), Harmful (EU). Harmful if swallowed. Target organ(s): Smooth muscle.

EYE

May cause eye irritation.

SKIN

May be harmful if absorbed through skin. May cause skin irritation.

INGESTION

Harmful if swallowed.

INHALATION

Harmful if inhaled. Material may be irritating to mucous membranes and respiratory tract.

CHRONIC

 

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

6.1
HAZARD CLASS

1544

PACKING GROUP

III

HAZARD SYMBOL

XN

RISK PHRASES

22

SAFETY PHRASES

22

 

EXTERNAL LINKS & GENERAL INFORMATION
Pharmacology: Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Mechanism of Action: Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy. (http://www.drugbank.ca/)

Paperverine is a smooth muscle relaxant. It belongs to the group of medicines called vasodilators. Vasodilators cause blood vessels to expand, thereby increasing blood flow, and are used to treat problems resulting from poor blood circulation. Papaverine is an opium alkaloid found in the opium poppy, but papaverine differs in both structure and pharmacological action from the other opium alkaloids. (http://www.hull.ac.uk/)

Drotaverine hydrochloride is an analogue of papaverine with smooth muscle relaxant properties. It is a non-anticholinergic antispasmodic, which selectively inhibits phosphodiesterase IV and is accompanied by a mild calcium channel-blocking effect. Adverse effects with drotaverine hydrochloride, such as hypotension, vertigo, nausea, and palpitation, are mostly mild. It can be supposed that intravenous drotaverine hydrochloride might be a feasible antimotility alternative to intravenous hyoscine-N-butylbromide in ERCP. But there is no clear evidence to recommend the use of drotaverine hydrochloride as an antispasmodic during ERCP. The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP. The effects of drotaverine hydrochloride on facilitative cannulation and its adverse effects were also compared to hyoscine-N-butylbromide. (http://clinicaltrials.gov/)

 

 

SALES SPECIFICATION

APPEARANCE

white crystalline powder

ASSAY

98.5 - 100.5%

MELTING POINT

225 - 227 C

HEAVY METALS

20ppm max

RESIDUE ON IGNITION

0.1% max

LOSS ON DRYING

0.5% max
pH

3.0 - 5.5

 

PACKING

 

 

PRICE

Papaverine hydrochloride 5kgs: U$2,500.- , Drotaverine hydrochloride 5kgs: U$1,900.-